CLINUVEL PHARMACEUTICALS
Information

CLINUVEL PHARMACEUTICALS

ISIN
AU000000CUV3
Ticker
CUV
ISIN
AU000000CUV3
Ticker
CUV
New Post

Information

stock small cap
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company. The Company is focused on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders, as well as healthcare solutions for the general population. The Company’s principal activity consists of commercializing and distribution in Europe and the United States of its drug candidate SCENESSE for the treatment of a rare, genetic metabolic disorder erythropoietic protoporphyria (EPP). It is also focused on developing and commercializing SCENESSE as a combination with narrowband ultraviolet B (NB-UVB) phototherapy and topical pharmaceutical formulations of melanocortin analogues for the treatment of the skin depigmentation disorder vitiligo. Its research and development of PRENUMBRA, a new liquid formulation of afamelanotide for the treatment of acute disorders and vascular anomalies.
Employees
16
Industries
Biotechnology & Drugs
Sector
Other

Community

Financials

52W Low
$13.74
52W High
$30.83
Market Capitalization
A$1.42B
EBITDA
A$30.52M
Beta
0.5077

Analyst Ratings

Target Price
A$33.92
This security is covered by 3 analysts
Buy
0
Hold
3
Sell
0

Dividends

Activities

Trending